Ultragenyx Pharmaceutical (RARE) Other financing activities (2014 - 2025)

Ultragenyx Pharmaceutical (RARE) has reported Other financing activities for 12 consecutive years, with $6.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Other financing activities rose 50.0% year-over-year to $6.0 million; the TTM figure through Dec 2025 stood at $17.0 million (up 54.55% YoY), while the FY2025 annual figure was $6.0 million, down 45.45% from the prior year.
• Other financing activities rose to $6.0 million in Q4 2025 per RARE's latest filing, from $4.0 million in the prior quarter.
• Across five years, Other financing activities topped out at $40.5 million in Q4 2021 and bottomed at -$25.9 million in Q3 2021.
• Historically, Other financing activities has averaged $4.1 million across 5 years, with a median of $28000.0 in 2023.
• On a YoY basis, Other financing activities climbed as much as 44263.79% in 2021 and fell as far as 239.39% in 2021.
• Ultragenyx Pharmaceutical's Other financing activities stood at $40.5 million in 2021, then plunged by 98.92% to $436000.0 in 2022, then sank by 93.58% to $28000.0 in 2023, then soared by 14185.71% to $4.0 million in 2024, then jumped by 50.0% to $6.0 million in 2025.
• Business Quant data shows RARE's Other financing activities at $6.0 million in Q4 2025, $4.0 million in Q4 2024, and $7.0 million in Q3 2024.